Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.
Saved in:
| Title: | Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies. |
|---|---|
| Authors: | Lopez JS; Drug Development Unit, Institute of Cancer Research and the Royal Marsden Hospital, London SW7 3RP, UK. Electronic address: juanita.lopez@icr.ac.uk., Milhem M; Department of Internal Medicine, Division of Hematology/Oncology and BMT, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA., Butler MO; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto M5G 2M9, ON, Canada; Departments of Medicine and Immunology, University of Toronto, Toronto M5G 2M9, ON, Canada., Thistlethwaite F; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M20 4GJ, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK., Van Tine BA; Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA., D'Angelo SP; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA., Johnson ML; Lung Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN 37203, USA., Sato T; Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Jefferson University, Philadelphia, PA 19107, USA., Arkenau HT; Phase-1 Trials Unit, Sarah Cannon Research Institute, UCL Cancer Institute, University College London, London W1G 6AD, UK., Edukulla R; Biometrics, Immunocore, Gaithersburg, MD 20878 USA., Wustner J; Translational Medicine, Immunocore, Conshohocken, PA 19428 USA., Marshall S; Clinical Development, Immunocore, Gaithersburg, MD 20878 USA., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston 77030, TX, USA. |
| Source: | Cell reports. Medicine [Cell Rep Med] 2025 Apr 15; Vol. 6 (4), pp. 101994. Date of Electronic Publication: 2025 Mar 06. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
